Question thread · 2 questions
Whether the drug Trastu'umab (Herceptin) will be made available to health boards for the treatment of metastatic breast cancer.
Started with S1W-09625 on 5 Sep 2000; latest 28 Nov 2000. Each later question says it follows up an earlier answer.
Follow-ups
1
Span
84 days
Answered
2 of 2
Asked by
1
The thread, in order
Each answer’s opening lines; open a question for the full text-
To ask the Scottish Executive whether the drug Trastu'umab (Herceptin) will be made available to health boards for the treatment of metastatic breast cancer.
Susan Deacon, 15 Nov 2000: The treatment of patients with breast cancer is a matter for specialists experienced in the management of cancer and the question of whether individual patients might benefit from treatment with Trastuzumab (Herceptin) is a matter for the clinical judgement of the specialist concerned. -
What criteria are used by specialists to determine whether or not, in their clinical judgement, a patient should receive Transtu'mab (Herceptin) for the treatment of metastatic cancer and whether such criteria are standardised and practised across all health boards.
Susan Deacon, 23 Jan 2001: It is not possible to define precisely the criteria used by specialists in deciding whether an individual patient should receive Transtuzmab (Herceptin). The ultimate judgement regarding the use of a particular treatment will be made by the specialist in discussion with the patient, or the patient's carer, taking into…
How this thread is put together
- Follow-up
- A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
- Several citations
- When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
- Thread
- Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.